AKT1型
对接(动物)
自动停靠
系统药理学
计算机科学
计算生物学
小桶
作用机理
PI3K/AKT/mTOR通路
药理学
生物
药品
医学
信号转导
生物化学
护理部
基因
转录组
基因表达
生物信息学
体外
作者
Shi-Yao Chen,Shuang Zhang,Rufan Cao,Xinyu Zhang,Liangqing Guo,Xiaochun Han
出处
期刊:
[Institute of Electrical and Electronics Engineers]
日期:2023-12-05
卷期号:: 4542-4546
标识
DOI:10.1109/bibm58861.2023.10385543
摘要
Objective To explore the target and mechanism of Qiwei Baizhu San in the treatment of type 2 diabetes based on network pharmacology integrating macromolecular docking. Methods The active ingredient and their corresponding action targets of Qiwei Baizhu San were obtained from TCMSP database, and the target genes of type 2 diabetes were obtained from Genecards and OMIM database. The intersection of the two was taken to obtain the action targets of the active ingredients of Qiwei Baizhu San in the treatment of T2DM. Cytoscape 3.9.1 was used to analyze the target PPI and draw a "drug-component-common target" network diagram to screen the core components; conduct Reactome, Wiki, KEGG Pathways analysis on the target using STRING database, and conduct GO analysis on Metascape; use Autodock and PyMol software for Macromolecular docking and visualization. Result Qiwei Baizhu San has a total of 57 active ingredients and 202 intersection targets with T2DM. Key targets mainly include AKT1, TP53, HSP90AA1, MAPK1, etc., which are mainly enriched in PI3K-Akt, MAPK, interleukin and other pathways. Macromolecular docking results show that key core components have good binding with core targets. Conclusion Qiwei Baizhu San can act on AKT1, MAPK1 and other targets to treat type 2 diabetes through active ingredients such as quercetin, kaempferol, luteolin, and formononetin, and play a multi-target and multi-pathway therapeutic role.
科研通智能强力驱动
Strongly Powered by AbleSci AI